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Background: The combination of the new high sensitivity troponin T (hsTnT) assays and copeptin, a biomarker of
endogenous stress, has been suggested to have the potential of early rule-out of acute coronary syndrome (ACS).
The aim of this study was to examine the ability of this combination to rule out ACS in patients presenting with
chest pain and to compare the diagnostic performance to hsTnT alone.
Method: In this prospective observational study, patients with chest pain admitted for observation were
consecutively included. Patients presenting with ST elevation were excluded. Copeptin and hsTnT were analyzed at
admission and hsTnT was thereafter determined approximately every 3rd hour as long as clinically indicated. The
follow-up period was 60 days. A combined primary endpoint of ACS, non-elective percutanous coronary
intervention, non-elective coronary artery bypass surgery and death of all causes was used.
Results: 478 patients were included. 107 (22%) patients were diagnosed with ACS during hospital stay. 70 (14%)
had non-ST-segment elevation myocardial infarction (NSTEMI) and 37 (8%) had unstable angina pectoris (UAP).
The combination of hsTnT >14 ng/L or copeptin ≥14 pmol/L at admission identified ACS with a higher sensitivity
than hsTnT alone: 0.83 (95% confidence interval (CI): 0.74-0.89) versus 0.69 (95% CI: 0.59-0.77), p <0.001. Negative
predictive values (NPV) 91% (95% CI: 86-94) versus 89% (95% CI: 84-92). A repeated hsTnT analyzed 3-4 hours after
admission resulted in a sensitivity of: 0.77 (95% CI: 0.65-0.86), p =0.031 for comparison with the combination
analyzed at admission.
Conclusions: In patients presenting with chest pain admitted for observation, the combination of hsTnT and
copeptin analyzed at admission had a significantly higher sensitivity to diagnose ACS than hsTnT alone. We report a
sensitivity of 83% and a NPV of 91% for the combination of hsTnT and copeptin and we conclude that biomarkers
alone are not sufficient to rule out ACS. However, the combination of hsTnT and copeptin seems to have a
significantly higher sensitivity to identify ACS than a repeated hsTnT test, and thus enables an earlier risk
stratification of chest pain patients. This can be time-saving and beneficial for the individual patient by contributing
to early decisions on treatment, need of further assessment and level of care.
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The leading symptom of an acute coronary syndrome
(ACS) is typically chest pain. Since ACS is associated with
a significant mortality and morbidity, correct diagnosis is
of great importance [1]. Chest pain is a frequent symptom
in medical emergency departments and distinguishing pa-
tients with ACS within the chest pain group is a diagnostic
challenge. Patients with suspected ACS account for a sub-
stantial proportion of all acute medical hospitalizations and
accordingly cause large costs for the health care system and
inconvenience for the individual patient [2]. Cardiac tropo-
nins and electrocardiography (ECG) in combination with
the medical history and physical examination are at present
the diagnostic cornerstones. In recent years, high sensitivity
troponin (hsTn) tests have been introduced [3,4], and it has
been suggested that a rapid rule-out protocol with a second
sample of hsTn after 3 hours is sufficient [1].
In the ideal scenario, ACS could be ruled out with
sufficient accuracy already at presentation. A copeptin
sample in combination with a cardiac troponin test has
been suggested for such early rule-out [5,6].
Cardiac troponins are released after myocardial cell
disintegration and are markers of cell necrosis. This may
be the reason for the relative weakness in diagnostic per-
formance in patients presenting early after chest pain
onset. The antidiuretic hormone arginin-vasopressin is
secreted by the neurohypophysis and controls osmotic
hemostasis. Copeptin, a relatively novel biomarker, is the
c-terminal of the vasopressin precursor hormone and is
co-secreted with the hormone [7]. Copeptin has a longer
half-life than vasopressin, which makes it easier to detect
and it directly reflects vasopressin release. Vasopressin, and
thereby copeptin, is released by endogenous stress and
increase immediately after chest pain onset [7-9]. The com-
bination of a marker of endogenous stress and a marker of
cell necrosis has been suggested to improve the diagnostic
performance in chest pain patients at presentation in the
emergency department [5,6].
Some publications address the potential benefit of the
combination of troponin and copeptin to safely rule out
ACS already at presentation [5,6,10-15]. The key find-
ings in these studies are that the addition of copeptin to
cardiac troponin seems to allow an early and reliable
rule out of AMI. Although suggestive of a potential
usefulness of the combination, these studies have either
included few patients [10,13,16], used the conventional
(4th generation) troponin assays [5,12,16,17], included
ST elevation myocardial infarction (STEMI) patients
[5,6,10-12] in which biomarkers are of less value, or
have only ruled out acute myocardial infarction (AMI)
and not the entire ACS population including unstable
angina pectoris (UAP) [5,10-12,14,15]. Therefore further
studies with sufficient number of patients, using high
sensitivity troponin, with clinically relevant endpointsand including UAP patients are needed before copeptin
can be safely introduced in routine clinical practise.
The aim of this study was to examine the ability of the
combination of copeptin and high sensitivity troponin T
(hsTnT) to rule out ACS in patients presenting with chest




The Skane University Hospital in Lund serves as the pri-
mary hospital for approximately 290 000 inhabitants. The
hospital has a cardiac intensive care unit with 19 beds and
an observation unit with ECG monitoring at 20 beds.
Percutanous coronary intervention and coronary artery
bypass surgery are available 24 hours a day. The emergency
department handles approximately 65000 patient visits per
year and 6500 of these present with chest pain. Ambulance
ECGs are sent to the cardiologist on call and all STEMI
identified are sent directly to the angiography laboratory,
bypassing the emergency department.
Inclusion of patients
During the period of March to July 2011, patients >18 years
with chest pain as the primary symptom and who were
admitted for observation for suspected ACS were consecu-
tively included. Patients discharged directly after the initial
assessment were not enrolled in this study. We excluded
patients with STEMI, patients with cardiac arrest during
the stay in the emergency department and patients with no
available follow up. The study was approved by the regional
ethics committee in Lund, Lund university (www.epn.se),
registry number 2010/429. The regional ethics committee
did not request an informed consent.
Routine clinical assessment and biochemical analysis
All patients underwent routine assessment according to
the hospital standards, including physical examination,
12-lead ECG and laboratory analyses including hsTnT.
All patients were observed with continuous ECG moni-
toring, pulse oxymetry and non-invasive blood pressure
measurements. Blood samples for hsTnT were collected
at admission and thereafter mainly at 3-4 and 5-6 hours
from admission according to the hospital routines, or as
long as clinically indicated.
In included patients, blood samples drawn at admission
were collected and troponin T was determined directly,
while copeptin samples were frozen and analyzed later.
Copeptin values were analyzed using the BRAHMS
copeptin kryptor assay, with a detection limit of 4.8
pmol/L, with a measuring range of 4.8 to 1200 pmol/L
and an interassay CV <15% for values <20 pmol/L and
an interassay CV <8% for values >50 pmol/L. A copeptin
value of <14 pmol/L was used as diagnostic cut-off point
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turer’s recommendation. The hsTnT method used was
Roche high sensitivity troponin T, with a detection limit
of 5 ng/L, with a measuring range of 3-10000 ng/L and an
interassay CV of 2%. A troponin T value of ≤14 ng/L was
used as diagnostic cut-off point in accordance with current
guidelines [1] and the hospital laboratory instructions.
Data collection and definitions of complications
Variables to calculate GRACE (Global Registry of Acute
Cardiac Events) risk score [18] were obtained from
hospital records.
Patients who were hypoxic and received treatment with
intravenous diuretics or cPAP (continuous positive airway
pressure) were classified as having heart failure demanding
treatment. A bleeding requiring blood transfusion was
classified as a major bleeding. Ventricular fibrillation,
ventricular tachycardia and hemodynamic significant
bradycardia were defined as malignant arrhythmia.
Adjudication of the final diagnosis and follow-up
The discharge diagnosis (including the ICD10 code) was
made by the responsible specialist ward physician and
was obtained from the discharge summary. The final dis-
charge diagnosis was adjudicated by the authors, blinded
for copeptin, using all available data. In 5 cases the dis-
charge diagnosis was changed from non-ST elevation
myocardial infarction (NSTEMI) to UAP and in 6 cases
the diagnosis was changed from UAP to NSTEMI.
The follow-up period was 60 days. A combined primary
endpoint of ACS, non-elective percutanous coronary
intervention, non-elective coronary artery bypass surgery
and death of all causes was used.
The diagnostic criteria for ACS (NSTEMI and UAP)
were those recommended by the Swedish national
registry for cardiac intensive care (Riks-HIA), which is
based on international guidelines from the European
Society of Cardiology and the American Heart Association
[1,19]. Unstable angina pectoris was defined as typical
chest pain history with either STT-changes (T-inversion
or ST-depression) or normal ECG, together with nor-
mal hsTnT values (≤14 ng/L) or elevated hsTnT values
without a significant rising or falling pattern. If the
hsTnT concentration was elevated near the cut-off
value (between 15-50 ng/L) a 50% change was considered
significant. For the diagnosis of UAP a coronary angi-




Continuous variables are presented as medians with the
inter-quartile range and compared with the Mann-Whitney
test. Categorical variables are presented as numbersand percentages and compared with the Pearson Chi-
square test.
Assessment of the diagnostic performance of high
sensitivity troponin and copeptin
Biomarkers were treated as categorical variables (positive
or negative).
Sensitivity, specificity, negative predictive values (NPV)
and positive predictive values (PPV) with 95% confidence
intervals were calculated. Sensitivity and specificity were
compared with McNemar test or Pearson Chi-square test.
All tests were two-tailed and a p-value <0.05 was
regarded as statistically significant.
All statistical analyses were performed with the use of
IBM SPSS Statistics 18.
Results
Baseline characteristics, outcome and final diagnosis
A total of 493 patients were enrolled in this study and
15 were excluded, 10 with STEMI and 5 with no available
follow up. In all 478 patients aged 18-96 years old were in-
cluded. Baseline characteristics of these patients are shown
in Table 1. Patients with ACS were older, had higher values
of creatinine and had higher GRACE scores. Furthermore,
in the ACS group there was a higher prevalence of male
sex, hypertension and hyperlipidemia.
The outcomes for the included patients relative to
troponin and copeptin values are shown in Table 2.
107 (22%) patients were diagnosed with ACS during
hospital stay, 70 (14%) had NSTEMI and 37 (8%) had UAP.
The diagnoses in the 371 patients who did not have ACS
were cardiac symptoms from other causes than coronary
artery disease in 28% (e.g. atrial fibrillation, stable angina
pectoris, congestive heart failure, perimyocarditis), non-
cardiac causes in 19% (e.g. musculoskeletal pain, pulmonary
embolism, dyspepsia, pneumonia) and chest pain of
unknown origin in 53%.
5 patients died during the hospital stay and a total of 9
(2%) patients died during the entire study period. All of
these patients had elevated troponin values and copeptin
values at presentation. The causes of death during the
hospital stay were aortic dissection, pulmonary embolism,
suspected myocardial infarction and 2 cases of sepsis. The
causes of death after discharge were trauma, sepsis and
unknown in 2 cases.
High sensitivity troponin T and copeptin measurements
The diagnostic performance of hsTnT versus the combi-
nation of hsTnT and copeptin at admission is presented in
Table 3. The sensitivity to detect ACS was significantly
increased using the combination of hsTnT and copeptin
and this applied to both NSTEMI and UAP. The increased
sensitivity resulted in a lowered specificity and the NPV
was only slightly increased when using the combination.
Table 1 Baseline characterisctics and presentation in the study population and according to final diagnosis
All ACS Not ACS p-value
(n = 478) (n = 107) (n = 371) (ACS vs not ACS)
General
Age (years) 66 (55-76) 68 (61-78) 65 (54-75) 0.012
Male sex 299 (63) 78 (73) 221 (60) 0.012
Medical history
Hypertension 256 (54) 69 (65) 187 (54%) 0.01
Hyperlipidemia and/or use of statins 185 (39) 54 (51) 131 (35) 0.005
Diabetes 99 (21) 27 (25) 72 (19) 0.19
Smokers 69 (17) 16 (16) 53 (17) 0.84
Ischemic heart disease 184 (39) 47 (44) 137 (37) 0.19
Prior PCI 101 (21) 24 (22) 77 (21) 0.71
Prior CABG 59 (12) 13 (12) 46 (12) 0.95
Stroke/TIA 52 (11) 12 (11) 40 (11) 0.9
Moderate to severe heart failure, EF < 35% 42 (9) 7 (7) 35 (9) 0.35
On presentation
Systolic blood pressure (mmHg) 146 (130-163) 155 (140-172) 143 (130-160) <0.001
Diastolic blood pressure (mmHg) 80 (75-90) 85 (78-97) 80 (74-90) 0.007
Heart rate (beats/minute) 78 (68-90) 78 (67-89) 77 (69-91) 0.7
ST depression 36 (8) 18 (17) 18 (5) <0.001
T-wave inversion 40 (8) 17 (16) 23 (6) 0.001
New LBBB 1 0 1
New RBBB 5 0 5
CRP (mg/L) 2.1 (0.8-6.7) 2.2 (0.9-4.8) 2.0 (0.76-6.9) 0.87
Creatinine (μg/L) 84 (70-100) 89 (77-107) 82 (69-97) 0.002
Cholesterol (mmol/L) 4.6 (3.7-5.4) 4.6 (3.9-5.5) 4.6 (3.3-5.4) 0.47
GRACE score 104 (82-132) 115 (96-137) 103 (78-130) 0.002
Copeptin (pmol/L) 12 (7-21) 16 (9-30) 12 (7-19) <0.001
High sensitivity Troponin T (ng/L) 10 (5-25) 25 (13-84) 7 (5-18) <0.001
PCI percutaneus coronary intervention, CABG coronary artery bypass grafting, TIA transient ischemic attack, LBBB left bundle branch block, RBBB right bundle branch
block, GRACE global registry of acute cardiac events. Data presented as n (%) of patients or median and 25th-75th interquartile range for continous variables.
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first sample, was available in 309 patients. In Table 4 the
comparison in diagnostic performance between hsTnT and
copeptin at admission and a repeated hsTnT test after 3-4
hours is shown. Both methods seemed to be equivalent in
the NSTEMI subgroup, while the use of the combination
resulted in a higher sensitivity in the UAP subgroup.
This resulted in a significantly higher sensitivity to iden-
tify ACS with the combination of hsTnT and copeptin
than with a repeated hsTnT test. Again, this was at the
cost of lower specificity.
Copeptin values related to final diagnosis are shown in
Table 5.
Discussion
In this prospective observational study, copeptin in com-
bination with high sensitivity troponin T at admission hada higher sensitivity to identify ACS than hsTnT alone and
the use of the combination at admission was found to be
equivalent to, or better than, a renewed hsTnT after 3-4
hours. In the NSTEMI subgroup the sensitivity was as
high as 98% with a NPV of 99% and this finding is in line
with several other studies [5,6,12,14,16,17].
Fewer studies have focused on the entire ACS population.
Keller et al. [6] reported a NPV of 80% in the ACS popula-
tion when combining a 4th generation troponin T test and
copeptin. In a relatively small study (n = 58) with high
proportion ACS [13] it was reported a sensitivity of 87%
and a NPV of 83% when combining hsTnT and copeptin at
admission and this was comparable to a second hsTnT sam-
ple after 3 hours. These results are similar to our findings.
Although the sensitivity is significantly increased, it is
important to note that the NPV increases only slightly,
by a few percentages, and this finding is also consistent
Table 2 Complications during study period and outcome related to troponin and copeptin values
hsTnT ≤ 14 and
Copeptin < 14
hsTnT > 14 or
Copeptin ≥ 14
hsTnT > 14 and
Copeptin ≥ 14
All
Total number of patients n = 204 n = 161 n = 113 n = 478
Complications
Heartfailure demandning treatment 3 (2) 9 (6) 17 (15) 29 (6)
Major bleeding 2 (1) 3 (2) 7 (6) 12 (3)
Malign arrythmia 3 (2) 3 (2) 8 (7) 14 (3)
Outcome during hospital stay
ACS 18 (9) 42 (26) 47 (42) 107 (22)
NSTEMI 3 (2) 30 (19) 37 (33) 70 (14)
Unstable angina pectoris 15 (7) 12 (7) 10 (9) 37 (8)
Coronary angiography with significant stenosis 18 (9) 35 (22) 36 (32) 89 (19)
Coronary angiography without significant stenosis 8 (4) 17 (11) 5 (4) 30 (6)
PCI 11 (5) 23 (14) 27 (24) 61 (13)
CABG 7 (3) 9 (6) 9 (8) 25 (5)
Cardiovascular death 0 (0) 0 (0) 1 (1) 1 (0,2)
Non cardiovascular death 0 (0) 0 (0) 4 (4) 4 (1)
Outcome after 60 days of follow up
ACS during follow up, excluding hospital stay 1 (0,5) 4 (2) 4 (4) 9 (2)
Coronary angiography with significant stenosis during follow up 0 (0) 3 (2) 2 (2) 5 (1)
PCI during follow up 0 (0) 0 (0) 1 (1) 1 (0)
CABG during follow up 0 (0) 3 (2) 0 (0) 3 (0,5)
Death during follow up, excluding hospital stay 0 (0) 0 (0) 4 (4) 4 (1)
Combined endpoint 19 (9) 45 (28) 55 (49) 119 (25)
ACS acute coronary syndrome, NSTEMI non ST-elevation myocardial infarction, PCI percutaneus coronary intervention, CABG coronary artery bypass grafting.
Data presented as n (%) of patients. Complications are defined in methods. A combined endpoint of ACS, non-elective PCI, non-elective CABG and death of all
causes was used.
Troponin is presentetd in the unit ng/L and copeptin in pmol/L.
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patients, the combination of hsTnT and copeptin de-
creased the number of false negative tests by 15 as com-
pared to hsTnT alone. This was at a cost of 74 more
false positives. Since our study population consisted of
only admitted patients and the intention was to identify
patients who may be discharged early, we argue that de-
creasing the amount of false negatives is of importance
to maintain an appropriate level of safety.
Overall it seems as if copeptin, a marker of endogen-
ous stress, adds diagnostic information in ACS and that
the combination of copeptin and hsTnT is equivalent to,
or better than, a second hsTnT value measured 3-4
hours after admission. In the ESC guidelines a rapid rule
out of AMI with a second hsTnT after 3 hours is sug-
gested [1]. Our results indicate that hsTnT and copeptin
analysed at admission, with a NPV of 99%, can be used
to rule out AMI with a very high accuracy, and thus
makes a second hsTnT unnecessary.
A clinical problem is the UAP patients, where 24 out
of 37 patients in our material were hsTnT- negative atadmission. Our study is the first larger study using the
combination of hsTnT and copeptin addressing this
issue. Reichlin et al. [5] report no significant difference
in copeptin concentration between UAP patients and pa-
tients with other diagnosis than ACS and attributes this
to that UAP does not cause sufficient endogenous stress
for vasopressin release. In our material (Table 5), al-
though not statistically significant, the trend was that
copeptin values are higher in the UAP patients com-
pared to the non-ACS group, and the addition of
copeptin detects 9 of the 24 hsTnT-negative UAP pa-
tients. Similar effects when adding copeptin have been
reported by other authors [6,13].
If rule out had been based on the combination of
hsTnT and copeptin alone, 18 (3 NSTEMI and 15 UAP)
out of 107 patients with ACS would have been
misdiagnosed as non-ACS. In other words, 9% of the
patients who were hsTnT and copeptin negative had a
significant stenosis when undergoing a coronary angi-
ography. Most will probably agree that this is too many
and we come to the conclusion that biomarkers alone
Table 4 Sensitivity, specificity and predicitve values of high
sensitive troponin T analyzed 3 to 4 hours after admission
and the combination of troponin and copeptin at admission
in the final diagnosis of ACS, NSTEMI and UAP
hsTnT ≤ 14 ng/L and
Copeptin < 14 pmol/L
at presentation
hsTnT ≤ 14 ng/L
after 3-4 hours
p-value
(n = 309) (n = 309)
ACS
Sensitivity 86 (74-92) 77 (65-86) 0.031
Specificity 50 (44-56) 68 (62-74) <0.001
NPV 92 (85-96) 91 (86-95)
PPV 33 (26-40) 41 (32-50)
NSTEMI
Sensitivity 98 (87-100) 98 (87-100) 1
Specificity 49 (43-55) 68 (62-73) <0.001
NPV 99 (95-100) 99 (96-100)
PPV 25 (19-32) 35 (27-44)
UAP
Sensitivity 61 (39-80) 35 (17-57) 0.031
Specificity 42 (37-48) 57 (51-63) <0.001
NPV 93 (87-97) 92 (86-95)
PPV 8 (5-13) 6 (3-12)
ACS acute coronary syndrome, NPV negative predicitive value, PPV positive
predicitive value, NSTEMI non ST-elevation myocardial infarction, UAP unstable
angina pectoris.
Sensitivity, Specificity, NPV and PPV are given with corresponding 95%
confidence interval.
Table 3 Sensitivity, specificity and predicitve values of
high sensitive troponin T and the combination of
troponin and copeptin in the final diagnosis of ACS,
NSTEMI and UAP
hsTnT ≤ 14 ng/L hsTnT ≤ 14 ng/L and
Copeptin < 14 pmol/L
p-value
ACS
Sensitivity 69 (59-77) 83 (74-89) <0.001
Specificity 70 (65-75) 50 (45-55) <0.001
NPV 89 (84-92) 91 (86-94)
PPV 40 (33-47) 32 (27-38)
NSTEMI
Sensitivity 87 (76-93) 96 (86-98) 0.031
Specificity 69 (65-74) 49 (44-54) <0.001
NPV 97 (94-98) 99 (95-99)
PPV 32 (26-40) 24 (19-30)
UAP
Sensitivity 35 (20-52) 59 (42-74) 0.004
Specificity 61 (56-66) 43 (38-48) <0.001
NPV 92 (88-95) 93 (87-95)
PPV 7 ( 4-12) 8 (5-12)
NPV negative predicitive value, PPV positive predicitive value, ACS acute
coronary syndrome, NSTEMI non ST-elevation myocardial infarction, UAP
unstable angina pectoris.
Sensitivity, Specificity, NPV and PPV are given with corresponding 95%
confidence interval.
Table 5 Copeptin values related to final diagnosis
Copeptin (pmol/L) p-value (vs not ACS)
Not ACS 12 (7-19)
ACS 16 (9-30) <0.001
NSTEMI 17 (9-44) <0.001
UAP 14 (9-23) 0.16
Data presented as median and 25th-75th interquartile range.
ACS acute coronary syndrome, NSTEMI non ST-elevation myocardial infarction,
UAP unstable angina pectoris.
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that 9 of these patients were identified with stress
testing, 7 based on history and ECG alone and 2 due to
increasing hsTnT values. As suggested in current guidelines
[1] we conclude that history, physical examination, ECG
and further evaluation with risk stratification, rule-out of
differential diagnosis and possible stress testing is needed.
The missed ACS were mainly UAP with negative troponin
during the hospital stay. Several previous studies have
shown that troponin negative ACS have much better prog-
nosis compared to troponin positive and may not be in
need of immediate admission [20]. It could be argued that
they could be discharged to later evaluation in the out-
patient clinic. For the high-risk group of troponin positive
(NSTEMI) patients the NPV at admission was excellent
(99%) for the combination missing only 1% of the NSTEMI
patients. Since our results indicate that we achieve the
same, or better, diagnostic accuracy with the combination
of hsTnT and copeptin at admission than with a repeated
hsTnT test, we suggest that clinical decisions regarding
further investigations (according to guidelines) should be
made already in the emergency department, saving at least
3 hours of observation.
Copeptin has also been suggested to be an independent
powerful prognostic factor in patients with known coronary
artery disease presenting with chest pain [15]. We foundthat the prognosis was good during 60 days follow-up, with
a low frequency of complications and no deaths (Table 2),
in the group with negative hsTnT and copeptin. Maybe the
combination of hsTnT and copeptin can be used to deter-
mine level of care, and allow early discharge in patients
without remaining symptoms, with planned follow-up
including a stress test when appropriate. This could in our
material prevent more than 40% of the admissions of
patients presenting with chest pain. It must, however, be
kept in mind that the good prognosis may in part be due to
that all patients with ACS in this group were intervened
during the hospital stay. Further studies where patients are
randomized to admission or discharge with follow-up are
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also include patients with UAP.
Study limitations
Firstly, this is a single-center study. However, as our
baseline characteristics are comparable to other studies
including consecutive patients presenting with chest pain
[4-6], we consider our results representative for unselected
patient cohorts presenting with chest pain.
Secondly, we have no data on chest pain onset and as
previously shown; copeptin is of greatest value early after
onset, with an immediate rise, a peak value within 3 hours
and a return to baseline in approximately 12 hours [6,9].
The clinical value of copeptin may therefore be greater in
early presenters. The pharmacokinetics might also, in pa-
tients with low peak values and delay from chest pain onset
to blood sampling, cause false negative results. However,
in these patients we expect that troponin has had time to
rise above the cut off value and in this way the analyses
supplement each other.
Thirdly, this is a prospective observational study and
therefore we cannot measure the clinical effects of a more
sensitive detection of ACS. Intervention studies are needed
to provide this important additional information.
Conclusions
The combination of hsTnT and copeptin analyzed at
admission had a higher sensitivity to diagnose ACS than
hsTnT alone and the use of the combination at admission
was found to be equivalent to, or better than, a renewed
hsTnT after 3-4 hours. The combination especially had a
strong potential to rule out NSTEMI whereas its capabil-
ity was weaker in the UAP population. We conclude that
biomarkers alone are not sufficient to rule out ACS, but
we suggest that the combination of hsTnT and copeptin
has the potential to help the clinician in the emergency
department to make safe and early decisions on further
investigations and on level of care. Furthermore, the use
of copeptin in addition to hsTnT may increase the diag-
nostic accuracy and signal a low risk of complications to
an extent where a larger proportion of chest pain patients,
in the emergency department, could be further evaluated
as outpatients. This could reduce the number of hospitali-
zations with subsequent lower costs and less inconvenience
for the single patient. Future research should address the
safety of such an approach.
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